ARPC4-TTLL3

Across TCGA pan-cancer cohorts, ARPC4-TTLL3 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of ARPC4-TTLL3’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where ARPC4-TTLL3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARPC4-TTLL3 is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

COAD, KIRP, and BRCA are the cancer types where ARPC4-TTLL3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARPC4-TTLL3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	All	II,III,IV	+0.364	<.001	10	view →
KIRP	All	All	+0.217	<.001	9	view →
BRCA	Female	All	−0.133	<.001	6	view →
CHOL	Male	All	+0.368	.002	4	view →
LIHC	All	All	+0.042	.007	4	view →
LUSC	All	All	−0.103	.017	2	view →
READ	Female	All	+0.286	.004	1	view →
LUAD	Male	III,IV	+0.211	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

ARPC4-TTLL3–COAD

Open the COAD breakdown →